|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.40 DKK | +3.09% |
|
+0.05% | -4.08% |
| 18/05 | Lundbeck's Asedebart Secures Orphan Drug Designation in Japan | MT |
| 18/05 | Lundbeck granted Orphan Drug Designation in Japan for asedebart | FW |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 131.8Cr | 191.6Cr | 229Cr | 314.3Cr | 319.2Cr | |||||
Depreciation & Amortization - CF | 36Cr | 37Cr | 39Cr | 39Cr | 38Cr | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 134.2Cr | 143.4Cr | 161.9Cr | 148.5Cr | 148.3Cr | |||||
Depreciation & Amortization, Total | 170.7Cr | 180.7Cr | 201.2Cr | 187.6Cr | 186.5Cr | |||||
(Gain) Loss on Sale of Investments - (CF) | - | - | - | - | - | |||||
Asset Writedown & Restructuring Costs | 30L | 40L | - | 55Cr | 64Cr | |||||
Stock-Based Compensation (CF) | - | - | - | - | - | |||||
Other Operating Activities, Total | -45Cr | 20Cr | 71Cr | 73Cr | 5.3Cr | |||||
Change In Accounts Receivable | 54Cr | -50Cr | -17Cr | -63Cr | -50Cr | |||||
Change In Inventories | -57Cr | -98Cr | -76Cr | 50Cr | -36Cr | |||||
Change in Other Net Operating Assets | -27Cr | 107.8Cr | -20L | -283.3Cr | 58Cr | |||||
Cash from Operations | 227.2Cr | 351.9Cr | 408Cr | 332.6Cr | 548.1Cr | |||||
Capital Expenditure | -41Cr | -37Cr | -28Cr | -51Cr | -55Cr | |||||
Sale of Property, Plant, and Equipment | 20L | 40L | 30L | 50L | 70L | |||||
Cash Acquisitions | - | -107.6Cr | - | -1.57TCr | - | |||||
Sale (Purchase) of Intangible assets | -20Cr | -45Cr | -22Cr | -5.7Cr | -6.4Cr | |||||
Investment in Marketable and Equity Securities, Total | - | - | - | 98Cr | - | |||||
Cash from Investing | -61Cr | -189.2Cr | -50Cr | -1.53TCr | -61Cr | |||||
Long-Term Debt Issued, Total | 40Cr | 123.4Cr | - | 1.25TCr | 371.6Cr | |||||
Total Debt Issued | 40Cr | 123.4Cr | - | 1.25TCr | 371.6Cr | |||||
Long-Term Debt Repaid, Total | -320.5Cr | -117.9Cr | -146.6Cr | -8.9Cr | -881.5Cr | |||||
Total Debt Repaid | -320.5Cr | -117.9Cr | -146.6Cr | -8.9Cr | -881.5Cr | |||||
Issuance of Common Stock | - | - | - | - | - | |||||
Repurchase of Common Stock | -3.4Cr | -4.5Cr | -4.3Cr | -4.6Cr | -2Cr | |||||
Common Dividends Paid | -50Cr | -40Cr | -58Cr | -69Cr | -94Cr | |||||
Common & Preferred Stock Dividends Paid | -50Cr | -40Cr | -58Cr | -69Cr | -94Cr | |||||
Cash from Financing | -333.6Cr | -39Cr | -208.5Cr | 1.16TCr | -606.2Cr | |||||
Foreign Exchange Rate Adjustments | 2.9Cr | 2.9Cr | -3.5Cr | -1.5Cr | -3.9Cr | |||||
Net Change in Cash | -164.5Cr | 126.9Cr | 146.2Cr | -35Cr | -123.1Cr | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 20Cr | 64Cr | 16Cr | 9.1Cr | 56Cr | |||||
Cash Income Tax Paid (Refund) | 45Cr | -7.1Cr | 47Cr | 58Cr | 142.2Cr | |||||
Levered Free Cash Flow | 308.72Cr | 50Cr | 293.62Cr | 455.62Cr | 393.9Cr | |||||
Unlevered Free Cash Flow | 318.29Cr | 57Cr | 297Cr | 462.69Cr | 426.02Cr | |||||
Change In Net Working Capital | -64Cr | 215.2Cr | 62Cr | -53Cr | 72Cr | |||||
Net Debt Issued / Repaid | -280.5Cr | 5.5Cr | -146.6Cr | 1.24TCr | -509.9Cr |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















